TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 99370165
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN plus ribavirin)
Study: 36065528
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen (specific medications not detailed)
Study: 36065528
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for infertility (specific medications not detailed)
Study: 35441466
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin produced by Bioton S.A. (0.3 units/kg)
Study: 35789270
Drug: trastuzumab-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab-based therapy
Study: 35789270
Drug: lapatinib-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lapatinib-based therapy
Study: 35789270
Drug: trastuzumab-lapatinib-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab-lapatinib-based therapy
Study: 35789270
Drug: trastuzumab-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab-based neoadjuvant therapy in NeoSphere cohort
Study: 33070223
Drug: 1 mM
Normalized name: PhaSeal Protector, 21 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mM l-carnitine
Study: 33070223
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without l-carnitine)
Study: 32514794
Drug: Nasal glucagon
Normalized name: glucagon Nasal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon (NG) 3 mg
Study: 32514794
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon (IMG) 1 mg
Study: 35831932
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (immunosuppressive therapy)
Study: 33766759
Drug: Soshiho-tang (SSHT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soshiho-tang (SSHT) administered three times a day for 4 weeks
Study: 35060622
Drug: Dynamic panel
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic panel model using structural equation modeling (ML-SEM)
Study: 39557549
Drug: In-person treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person treatment
Study: 36315226
Drug: Bioptron light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioptron light therapy for 12 minutes three times per week plus standard wound care
Study: 36240610
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of GH (SG), mean baseline GH dose of 0.13 mg/day increased to 0.31 mg/day at study end
Study: 34707496
Drug: Ejiao (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ejiao (6 g/day)
Study: 35575780
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medication workflow)
Study: 33847634
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) and methylene blue (MB) combination method
Study: 34412906
Drug: Pictograms on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictograms on prescription medication labels
Study: 34412906
Drug: Pictograms for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictograms for dose and route of administration, and dosage frequency
Study: 34650034
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus carboplatin and pemetrexed administered every three weeks for up to six cycles, followed by maintenance of toripalimab and pemetrexed.
Study: 33569770
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment for 48 weeks
Study: 37794803
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin with chemotherapy
Study: 34864978
Drug: Ultraslow thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25 hours)
Study: 34864978
Drug: Fast thrombolytic
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast thrombolytic regimen (50 mg of rtPA infused in 6 hours)
Study: 34162831
Drug: Clinical-stage orally
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical-stage orally administered drugs targeting inhibitor of apoptosis proteins
Study: 36321647
Drug: Calcipotriol‐Betamethasone Dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam with Ablative Fractional Laser (AFL) treatment
Study: 32138709
Drug: Propranolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol treatment in children with long-QT syndrome
Study: 83012907
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate (PN) 800 mg in two divided doses
Study: 34431926
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection with aspiration
Study: 33745625
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein group (1.6 g of protein/kg/day)
Study: 33745625
Drug: Low Protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Protein group (0.8 g of protein/kg/day)
Study: 35346353
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise program (60 min, once a week for 12 weeks, and self-exercise twice a week)
Study: 32430078
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (bi-weekly) including aerobic training, strengthening, and cardiovascular exercises for 8 weeks.
Study: 34737064
Drug: Sprifermin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprifermin (recombinant FGF18), administered intra-articularly over a 2-year period.
Study: 34737064
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered intra-articularly over a 2-year period.
Study: 34091813
Drug: Sublingual dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual dexamethasone 8 mg (2 ml) with normal saline administered 1 hour before surgery
Study: 34091813
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone 8 mg
Study: 35272334
Drug: Methenamine with
Normalized name: Methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine with cranberry capsules
Study: 32701140
Drug: Standard-of-care neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care neoadjuvant therapy consisting of taxane treatment followed by doxorubicin and cyclophosphamide.
Study: 32701140
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (taxane treatment without investigational agents).
Study: 32584180
Drug: butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: butorphanol tartrate (5 mg/kg)
Study: 35380376
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg) with ketamine (0.5 mg/kg) administered over 10 min followed by a maintenance dose of Dexmedetomidine (0.2‐0.8 µg/kg/h)
Study: 33016783
Drug: Herceptin® (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin® (6 mg/kg)
Study: 35545356
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) as an addition to usual care
Study: 33150320
Drug: Comparator vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator vaccine
Study: 35027515
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (GDT) protocol using DCO2 and SCvo2
Study: 33345953
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 10 L/min until delivery
Study: 35222905
Drug: Whole-body photobiomodulation
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body photobiomodulation (PBM) therapy programme
Study: 32461138
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (25,000 IU weekly for 26 weeks)
Study: 33606419
Drug: Predetermined volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predetermined volumes of a feeding-drink (Nutricia Nutridrink) between 50 and 400 ml
Study: 33780930
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group increased TWI to 3.7 L for males and 2.7 L for females for 14 days.
Study: 36695682
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol
Study: 33339752
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for 14 days
Study: 33031270
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of VASO6 (green tea extract)
Study: 33956802
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment supervision (control)
Study: 33109386
Drug: Hetrombopag 7.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag 7.5-mg tablets administered with high-fat, high-calorie food
Study: 33109386
Drug: Hetrombopag 7.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag 7.5-mg tablets administered in the fasted state
Study: 34287856
Drug: Parenteral anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral anticoagulation therapy (PACT)
Study: 34290173
Drug: Verapamil 2.5
Normalized name: verapamil 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 2.5 mg
Study: 32727162
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day Fish Oil (FO)
Study: 35130935
Drug: TtLIVE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TtLIVE intervention (multi-component virtual care solution including virtual home visits, customizable care plans, clinical workflows, digitally secure communication, resource library)
Study: 33527139
Drug: Standard glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucocorticoid therapy
Study: 34049911
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus calcium dobesilate (CaD) 500 mg three times per day for 12 months
Study: 33742792
Drug: Therapeutic touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic touch (TT) as a complementary therapy
Study: 32864805
Drug: Single-agent concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent concurrent chemoradiotherapy using S-1
Study: 32864805
Drug: Double-agent concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-agent concurrent chemoradiotherapy using S-1 and cisplatin
Study: 38517242
Drug: Anakinra treatment
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra treatment
Study: 35715405
Drug: Pembrolizumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab with chemotherapy
Study: 33151266
Drug: CTC-driven treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC-driven treatment choice (chemotherapy if ≥5 CTCs/7.5 mL; endocrine therapy if <5 CTCs/7.5 mL)
Study: 35498050
Drug: L-Arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine
Study: 34788571
Drug: Golodirsen 30
Normalized name: golodirsen
DrugBank: Golodirsen (DB15593)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Golodirsen 30 mg/kg
Study: 32621905
Drug: Integrated behavior
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated behavior therapy (video-based behavioral weight loss program and problem-solving therapy for depression)
Study: 36342151
Drug: Double sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double sequential external defibrillation (DSED)
Study: 34863776
Drug: RLRL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLRL treatment plus single-vision spectacle (SVS)
Study: 34863776
Drug: RLRL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLRL treatment
Study: 32202637
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily (BID)
Study: 32202637
Drug: Acalabrutinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 200 mg once daily (QD)
Study: 35764522
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding combined with quadruple therapy
Study: 35764522
Drug: Oral Weifuchun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Weifuchun Tablets with quadruple therapy
Study: 32388694
Drug: Control participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control participants received home-based EHS plus 10 weekly books
Study: 34563096
Drug: NUDT15 genotype-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUDT15 genotype-based dose optimisation (50% dose reduction for CT genotype, alternative drugs for TT genotype)
Study: 34460948
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg weekly subcutaneous)
Study: 34460948
Drug: Dupilumab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (in patients with baseline IgE ≥ 200 IU/ml)
Study: 37060024
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ACEIs)
Study: 34231846
Drug: DADEE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DADEE intervention (9-week program with weekly sessions plus home-based tasks)
Study: 34537124
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block using 20-cc 0.5% bupivacaine solution
Study: 34537124
Drug: p-TAP (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-TAP (placebo) using 20-cc isotonic solution
Study: 34284344
Drug: DCVAC/LuCa and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVAC/LuCa and chemotherapy (carboplatin and paclitaxel)
Study: 34284344
Drug: DCVAC/LuCa, chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVAC/LuCa, chemotherapy, pegylated interferon‐?2b, and hydroxychloroquine
Study: 32728771
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) lung cancer screening
Study: 34090781
Drug: Regenerative cell
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative cell therapy
Study: 32833128
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (150 min of moderate-intensity weekly exercise)
Study: 35590284
Drug: Oral pivmecillinam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pivmecillinam (PIV) 400 mg QID for 1 week after 3 days of parenteral antibiotics
Study: 34375336
Drug: Oral rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rotavirus vaccine
Study: 34375336
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement (MMS)
Study: 32917784
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg lanthanum carbonate thrice daily for 96 weeks
Study: 32917784
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo thrice daily for 96 weeks
Study: 32184305
Drug: WEE1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WEE1 inhibitor adavosertib (AZD1775) in combination with cisplatin chemotherapy preoperatively (group A)
Study: 32184305
Drug: WEE1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WEE1 inhibitor adavosertib (AZD1775) in combination with postoperative cisplatin-based chemoradiation (group B)
Study: 32184305
Drug: WEE1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WEE1 inhibitor adavosertib (AZD1775) in combination with cisplatin chemotherapy (group A)
Study: 33955686
Drug: GLPG1205 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 100 mg once daily for 12 days
Study: 33812492
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg per day) plus Mesalazine (2 g per day)
Study: 33812492
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo plus Mesalazine (2 g per day)
Study: 33812492
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo plus Mesalazine placebo
Study: 35732417
Drug: Shufeng Jiedu
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shufeng Jiedu capsule (SFJDC) for 7 days
Study: 36210622
Drug: 1 mmol/L
Normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol/L citrate
Study: 36210622
Drug: 3 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mmol/L acetate
Study: 32150758
Drug: Non-TEE-guided strategy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-TEE-guided strategy (edoxaban 60 mg once-daily or enoxaparin-warfarin)
Study: 33497075
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of corticosteroids (40 mg triamcinolone acetonide during surgery, placebo intravenous administration)
Study: 33497075
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of corticosteroids
Study: 33497075
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of corticosteroids
Study: 34898155
Drug: Topical stabilized
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical stabilized cysteamine (st.Cys)
Study: 32100043
Drug: Opiate analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate analgesics (medically prescribed or not)
Study: 32100043
Drug: Opiate analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate analgesics (not medically prescribed)
Study: 32165156
Drug: BAL-directed CF
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL-directed CF therapy
Study: 32865375
Drug: Early rhythm
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rhythm control (treatment with antiarrhythmic drugs or atrial fibrillation ablation)
Study: 35882513
Drug: Medication (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (medical management)
Study: 36294153
Drug: Partner support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partner support and initiating a planned quit attempt during treatment
Study: 32571602
Drug: One-on-one hand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-on-one hand therapy in addition to the handout
Study: 32681219
Drug: Intralesional meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional meglumine antimoniate (MA) weekly over 10 weeks
Study: 35672873
Drug: Ultrasound-guided curettage
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided curettage combined with hysteroscopic electro-resection after injection of pituitrin
Study: 35672873
Drug: Hysteroscopic electro-resection
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic electro-resection after methotrexate chemotherapy
Study: 34282125
Drug: Prolonged-exposure psychotherapy
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-exposure psychotherapy with hydrocortisone augmentation
Study: 34282125
Drug: Prolonged-exposure psychotherapy
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-exposure psychotherapy without hydrocortisone augmentation
Study: 33653149
Drug: Patching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching treatment for amblyopia
Study: 36521097
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment
Study: 34473373
Drug: Gender-specific instruction
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-specific instruction for female first responders (10 min oral delivery by a staff physician)
Study: 38697182
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy